Durability of sustained virologic response and improvement of fibrosis markers after daclatasvir and asunaprevir treatment in Genotype 1b Hepatitis C Virus-Infected Patients: A real life and multicenter study

Seung Kak Shin, Jin Woo Lee, Hannah Ra, Oh Sang Kwon, Jong Beom Shin, Young Joo Jin, Sangheun Lee, Ki Jun Han, Young Nam Kim, Tae Hun Kim, Yun Soo Kim, Ju Hyun Kim

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Background: The long-term data with direct acting antiviral agents were rare. This study investigated the durability of a sustained virologic response (SVR) and the improvement of fibrosis after daclatasvir and asunaprevir (DCV/ASV) treatment in genotype 1b (GT1b) hepatitis C virus (HCV)-infected patients. Methods: A total of 288 HCV GT1b patients without baseline non-structural 5A (NS5A) resistance-associated substitution (RAS) treated with DCV/ASV were enrolled. Virologic response was measured at 12 weeks and 1 year after treatment completion. In cirrhotic patients, liver function, aspartate transaminase to platelet ratio index (APRI), FIB-4 index, fibrosis index (FI), and liver stiffness measurement (LSM) at baseline and 1 year after treatment completion were evaluated. Results: SVR12 was obtained in 278 patients (96.5%). Six patients who checked NS5A RAS after treatment failure were RAS positive. Only one patient showed no durability of SVR. In cirrhotic patients who achieved SVR12 (n = 59), the changes of albumin (3.8 [2.2-4.7] to 4.3 [2.4-4.9] g/dL; P < 0.001), platelet count (99 [40-329] to 118 [40-399] × 103/mm3; P < 0.001), APRI (1.8 [0.1-14.8] to 0.6 [0.1-4.8]; P < 0.001), FIB-4 index (5.45 [0.6-32.8] to 3.3 [0.4-12.2]; P < 0.001), FI (5.5 [0.6-32.8] to 3.3 [0.4-12.2]; P < 0.001), and LSM (17.2 [5.3-48.0] to 11.2 [3.7-28.1] kPa; P = 0.001) between baseline and 1 year after treatment completion were observed. Conclusion: DCV/ASV treatment for HCV GT1b infected patients without RAS achieved high SVR rates and showed durable SVR. Cirrhotic patients who achieved SVR12 showed the improvement of liver function and fibrosis markers.

Original languageEnglish
Article numbere264
JournalJournal of Korean Medical Science
Volume34
Issue number41
DOIs
StatePublished - 2019

Bibliographical note

Publisher Copyright:
© 2019 The Korean Academy of Medical Sciences.

Keywords

  • Asunaprevir
  • Daclatasvir
  • Fibrosis
  • Hepatitis C Virus
  • Sustained Virologic Response

Fingerprint

Dive into the research topics of 'Durability of sustained virologic response and improvement of fibrosis markers after daclatasvir and asunaprevir treatment in Genotype 1b Hepatitis C Virus-Infected Patients: A real life and multicenter study'. Together they form a unique fingerprint.

Cite this